Similar articles

• Hematopoietic stem cell transplants for multiple myeloma.

  Tricot G, Jagannath S, Vesole DH, Bracy D, Desikan KR, Siegel D, Barlogie B. Tricot G, et al. Leuk Lymphoma. 1996 Jun;22(1-2):25-36. doi: 10.3109/10428199609051725. Leuk Lymphoma. 1996. PMID: 8724525 Review.
• [High-dose melphalan in patients with multiple myeloma].

  Moreau P, Le Bonniec M, Harousseau JL. Moreau P, et al. Bull Cancer. 1999 Mar;86(3):283-8. Bull Cancer. 1999. PMID: 10210762 Review. French.
• [Multiple myeloma and other plasma cell dyscrasias].

  del Potro Gómez E, Morales Sanz D. del Potro Gómez E, et al. Rev Clin Esp. 1999 Apr;199 Suppl 1:52-7. Rev Clin Esp. 1999. PMID: 10422451 Review. Spanish. No abstract available.
• "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.

  Gasparetto C, Gockerman JP, Diehl LF, de Castro CM, Moore JO, Long GD, Horwitz ME, Keogh G, Chute JP, Sullivan KM, Neuwirth R, Davis PH, Sutton LM, Anderson RD, Chao NJ, Rizzieri D. Gasparetto C, et al. Biol Blood Marrow Transplant. 2010 Jan;16(1):70-7. doi: 10.1016/j.bbmt.2009.08.017. Epub 2009 Sep 3. Biol Blood Marrow Transplant. 2010. PMID: 19733251 Clinical Trial.
• [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].

  Adam Z, Krejcí M, Pour L, Stepánková S, Cermáková Z, Voska L, Teplan V, Krivanová A, Hájek R, Mayer J. Adam Z, et al. Vnitr Lek. 2009 Nov;55(11):1089-96. Vnitr Lek. 2009. PMID: 20017442 Review. Czech.